{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06157151",
            "orgStudyIdInfo": {
                "id": "PRGN-2009-201"
            },
            "organization": {
                "fullName": "Precigen, Inc",
                "class": "INDUSTRY"
            },
            "briefTitle": "PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer",
            "officialTitle": "A Randomized, Open-label, Two-arm, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy in Patients With Recurrent or Metastatic Cervical Cancer.",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "prgn-in-combination-with-pembrolizumab-versus-pembrolizumab-in-patients-with-recurrent-or-metastatic-cervical-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-01-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-01-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-11-27",
            "studyFirstSubmitQcDate": "2023-11-27",
            "studyFirstPostDateStruct": {
                "date": "2023-12-05",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-16",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-17",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Precigen, Inc",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "National Cancer Institute (NCI)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This randomized trial will evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab compared to pembrolizumab alone in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.",
            "detailedDescription": "This is a randomized, two-arm study of PRGN-2009 in patients with recurrent or metastatic cervical cancer who are pembrolizumab resistant. Patients meeting all eligibility criteria who consent to participate in the study will be randomized 1:1 to receive a combination of PRGN-2009, plus pembrolizumab, or to receive pembrolizumab alone."
        },
        "conditionsModule": {
            "conditions": [
                "Cervical Cancer",
                "HPV-Related Carcinoma",
                "HPV-Related Malignancy",
                "Recurrent Cervical Carcinoma",
                "Metastatic Cervical Cancer"
            ],
            "keywords": [
                "Human Papilloma Virus",
                "Cervical Cancer",
                "Pembrolizumab",
                "Therapeutic Vaccine",
                "Cervix Cancer",
                "Resistance to Checkpoint Inhibitors"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "This is an open-label, randomized study.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 46,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "PRGN-2009 plus Pembrolizumab",
                    "type": "EXPERIMENTAL",
                    "description": "PRGN-2009 at a dose of 5 x 10\\^11 PU q3W for 3 administrations, then q6w, plus Pembrolizumab, 400mg q6w",
                    "interventionNames": [
                        "Biological: PRGN-2009 plus Pembrolizumab"
                    ]
                },
                {
                    "label": "Pembrolizumab alone",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Pembrolizumab, 400mg q6w",
                    "interventionNames": [
                        "Drug: Pembrolizumab alone"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "PRGN-2009 plus Pembrolizumab",
                    "description": "Subjects randomized will receive PRGN-2009 (5 x 10\\^11 PU, subcutaneous (SC) injection) every 3 weeks for three administrations, thereafter subjects will continue to receive PRGN-2009 administrations every 6 weeks. Pembrolizumab will be administered concurrently as intravenous (IV) infusion (400 mg) every 6 weeks.",
                    "armGroupLabels": [
                        "PRGN-2009 plus Pembrolizumab"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Pembrolizumab alone",
                    "description": "Subjects randomized will receive IV infusion of pembrolizumab (400 mg) administered every 6 weeks.",
                    "armGroupLabels": [
                        "Pembrolizumab alone"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Determine the Objective Response Rate (ORR) following treatment with PRGN-2009 in combination with pembrolizumab or pembrolizumab alone in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.",
                    "description": "The ORR will be calculated as the combination of subjects achieving a complete response or a partial response per RECIST v1.1.\n\nORR will be calculated and presented with 2-sided 95% confidence interval.",
                    "timeFrame": "1 year"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Safety of PRGN-2009 in combination with pembrolizumab or pembrolizumab alone",
                    "description": "Systemic toxicity will be assessed through the capture of Treatment Emergent Adverse Events ( TEAEs). The severity of the TEAEs will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE) v 5.0 scale.",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Progression-Free Survival (PFS) and Overall Survival (OS) following treatment with PRGN-2009 in combination with pembrolizumab or pembrolizumab alone",
                    "description": "Duration of PFS and OS will be summarized using the Kaplan-Meier Product Limit estimator along with the corresponding two sided-95% Confidence intervals.",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Best Overall Responses (BOR) and Disease Control Rate (DCR) per RECIST v1.1 following treatment with PRGN-2009 in combination with pembrolizumab or pembrolizumab alone",
                    "description": "The proportion of subjects with BOR and DCR will be summarized using descriptive statistics.",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Time to Response and Duration of Responses following treatment with PRGN-2009 in combination with pembrolizumab or pembrolizumab alone",
                    "description": "TTR and DOR will be summarized using descriptive statistics.",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Vector shedding following subcutaneous administration of PRGN-2009",
                    "description": "Samples collected before and at specific intervals after treatment will be evaluated for presence of adenoviral vector.",
                    "timeFrame": "Up to 4 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age 18 years and older.\n* Recurrent or metastatic cervical cancer (histologically or cytologically confirmed) that meets the criteria of pembrolizumab-resistant.\n* Must have been treated with pembrolizumab, either as monotherapy or in combination\n* Patients must have received no more than two prior systemic regimens in the recurrent or metastatic setting\n* Tumors are confirmed positive for PD-L1 and HPV16/18\n* Measurable disease that can be accurately measured by RECIST v1.1 criteria\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Life expectancy \u2265 12 weeks from the time of enrollment.\n* Must have adequate organ function\n* Negative serum pregnancy test. Women of child-bearing potential (WOCBP) must agree to use adequate contraception prior to study entry and for at least 6 months following completion of study treatment.\n* All patients must have the ability to understand and willingness to sign a written informed consent.\n\nExclusion Criteria:\n\n* Patients with presence of other active malignancy within 1 year prior to study entry\n* Known Central Nervous System (CNS) disease\n* Has severe hypersensitivity (\u2265Grade 3) to pembrolizumab and/or any of its excipients.\n* Known history of active tuberculosis (TB, Bacillus tuberculosis).\n* Pregnant and lactating women are excluded from this study.\n* Patients with a history of solid organ transplant.\n* Patients currently participating in a study of an investigational agent or have used an investigational device within 4 weeks prior to the first dose of study treatment.\n* Patients, who in the opinion of the investigator, may not be able to comply with the monitoring requirements of the study.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Amy Lankford",
                    "role": "CONTACT",
                    "phone": "3015569900",
                    "email": "clinicaltrials@precigen.com"
                }
            ],
            "locations": [
                {
                    "facility": "University of Arkansas for Medical Sciences",
                    "status": "RECRUITING",
                    "city": "Little Rock",
                    "state": "Arkansas",
                    "zip": "72205",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Michael Birrer, MD, PhD",
                            "role": "CONTACT",
                            "phone": "501-686-8522",
                            "email": "MJBirrer@uams.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.74648,
                        "lon": -92.28959
                    }
                },
                {
                    "facility": "National Institute of Health",
                    "status": "RECRUITING",
                    "city": "Bethesda",
                    "state": "Maryland",
                    "zip": "20892",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Erica Redmond",
                            "role": "CONTACT",
                            "email": "erica.redmond@nih.gov"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.98067,
                        "lon": -77.10026
                    }
                },
                {
                    "facility": "University of Washington",
                    "status": "RECRUITING",
                    "city": "Seattle",
                    "state": "Washington",
                    "zip": "98109",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "John Liao, MD",
                            "role": "CONTACT",
                            "phone": "866-932-8588",
                            "email": "cvitrial@uw.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 47.60621,
                        "lon": -122.33207
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000002583",
                    "term": "Uterine Cervical Neoplasms"
                },
                {
                    "id": "D000012008",
                    "term": "Recurrence"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000020969",
                    "term": "Disease Attributes"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000014594",
                    "term": "Uterine Neoplasms"
                },
                {
                    "id": "D000005833",
                    "term": "Genital Neoplasms, Female"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000002577",
                    "term": "Uterine Cervical Diseases"
                },
                {
                    "id": "D000014591",
                    "term": "Uterine Diseases"
                },
                {
                    "id": "D000005831",
                    "term": "Genital Diseases, Female"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "asFound": "Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M13131",
                    "name": "Papilloma",
                    "relevance": "LOW"
                },
                {
                    "id": "M14850",
                    "name": "Recurrence",
                    "asFound": "Recurrent",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5830",
                    "name": "Uterine Cervical Neoplasms",
                    "asFound": "Cervical Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17522",
                    "name": "Virus Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M22700",
                    "name": "Disease Attributes",
                    "relevance": "LOW"
                },
                {
                    "id": "M17342",
                    "name": "Uterine Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8945",
                    "name": "Genital Neoplasms, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5825",
                    "name": "Uterine Cervical Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17339",
                    "name": "Uterine Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8943",
                    "name": "Genital Diseases, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000582435",
                    "term": "Pembrolizumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M349416",
                    "name": "Pembrolizumab",
                    "asFound": "Mg/m2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17360",
                    "name": "Vaccines",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}